Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

Pages

19185 items
4:54 PM, Feb 23, 2018  |  BioCentury | Regulation

Herculean task for DMD

Driven by the delayed reimbursement decision for Europe’s only approved DMD therapy, the patient advocacy group Duchenne UK has brought together seven companies in the space to create a set of shared tools that should...
4:51 PM, Feb 23, 2018  |  BioCentury | Strategy

Patients as pawns

In an apparent game of chicken between Vertex Pharmaceuticals Inc. and French health authorities over the price of the cystic fibrosis drug Orkambi, patients say the decision to use access to investigational therapies as a...
4:49 PM, Feb 23, 2018  |  BioCentury | Politics, Policy & Law

Fiddling with Medicare

Looking for ways to fulfill its commitment to reduce drug costs, the Trump administration reached into a grab bag filled with Medicare reforms, pulled out a fist full and dropped them into its FY19 budget...
4:12 PM, Feb 23, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least four profitable biotechs and pharmas are slated to report earnings this week. CompanyDatePre/post mkt4Q17 EPS est4Q16 EPSExpected chgEndo International plc (NASDAQ:ENDP)2/27Pre$0.61$1.77-66%Jazz Pharmaceuticals plc (NASDAQ:JAZZ)2/27Post$3.01$2.7111%Bayer AG (Xetra:BAYN)2/28Pre€ 1.16€ 1.19-3%Valeant Pharmaceuticals International Inc. (NYSE:VRX;...
12:12 PM, Feb 23, 2018  |  BioCentury | Finance

Seeking maturity

In need of funds to support a series of pivotal trials and finding the domestic market inhospitable to biotech, Taiwan Liposome Co. Ltd. (TPEx:4152) has chosen NASDAQ for a second listing. On Feb. 16, the...
11:52 AM, Feb 23, 2018  |  BioCentury | Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
5:04 PM, Feb 22, 2018  |  BioCentury | Finance

Data-driven

Kallyope Inc.’s data-intensive approach to mapping the gut-brain axis led Two Sigma Ventures to join the biotech’s $66 million series B round, marking the VC’s second investment in therapeutics. Existing investor Lux Capital led the...
2:56 PM, Feb 22, 2018  |  BioCentury | Finance

Belgian Insights

Belgium has provided Europe with a host of pioneering biotechs, led by CEOs who have demonstrated resilience and stamina in the pursuit of homegrown innovation. The opening evening session on May 14 at Bio€quity Europe...
6:53 PM, Feb 16, 2018  |  BioCentury | Product Development

Necessary adjustment

Changing a pivotal trial’s primary endpoint analysis after the study is under way is usually not a good sign. So when Bristol-Myers Squibb Co. revealed top-line results from the CheckMate -227 trial in a biomarker-defined...
6:09 PM, Feb 16, 2018  |  BioCentury | Politics, Policy & Law

FDA’s bigger piggy bank

FDA plans to use a proposed record-setting funding boost to invest in projects it believes could lead to fundamental improvements in the way medical products are tested, reviewed and manufactured. The goal is to use...

Pages